Evidence map›Paper›PMID 32495011›Full record

ArticleEJNMMI research2020

Quantification and reliability of [

Zsolt Cselényi, Aurelija Jucaite, Cecilia Kristensson, Per Stenkrona, Pär Ewing, Andrea Varrone, Peter Johnström, Magnus Schou, Ana Vazquez-Romero, Mohammad Mahdi Moein and 8 more

Registry-linked trialAbstract read
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03097380 (An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03097380 phase1completednot on this map

An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.

TypeinterventionalSponsorAstraZenecaRan2017 to 2017Enrolled19ConditionsHealthy VolunteersArmsAZD2115, SPIRIVA, [11C]AZ13754366
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zsolt CselényiPET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden. Zsolt.Cselenyi@astrazeneca.com.ORCID https://orcid.org/0000-0002-8479-6282
Aurelija JucaitePET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Cecilia KristenssonBioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.
Per StenkronaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Pär EwingBioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.
Andrea VarroneDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Peter JohnströmPET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Magnus SchouPET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.
Ana Vazquez-RomeroDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Mohammad Mahdi MoeinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Martin BolinDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Jonathan SiikanenDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Pär GrybäckDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Bengt LarssonBioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Ken GrimeBioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.
Ulf G ErikssonBioPharmaceuticals R&D, AstraZeneca, Göteborg, Sweden.
Lars FardePET Science Centre, Precision Medicine, R&D, AstraZeneca, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe radioligand [

methodsPET measurements using [

resultsThe 1TCM was the statistically preferred model for description of [

conclusionsThe kinetic behaviour and good repeatability of [

trial registrationClinicalTrials.gov identifier: NCT03097380, registered: 31 March 2017.

Indexed as

[11C]VC-002LungsMuscarinic acetylcholine receptorsPositron emission tomographyTest-retest

Identifiers

PMID32495011
PMCPMC7270393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.